Ginkgo Bioworks, a.k.a. “the organism company,” has notched many milestones in its 13-year history, Fortune magazine reports. Founded by four Ph.D. students in bioengineering and computer science at MIT with their professor, the synthetic biology business has partnered with Fortune 500 giants to develop custom strains of organisms used to make everything from fragrances to fertilizers. They have collaborated with Roche to hunt for natural antibiotics in soil. They’ve worked with startups to engineer probiotics to treat disease and to break down plastic pollution. They’ve designed lab-grown proteins that make faux meat taste real. Now they share the story of taking their company public via a SPAC.
The company in May announced a business combination with Soaring Eagle Acquisition that values the engineered biology company at a $15 billion pre-money equity valuation and is expected to provide up to $2.5 billion of primary proceeds. Read more.
Related Posts
SPAC Warrant Restatements Won’t Hit Credit, Moody’s Says: Report
The credit strength of companies shouldn’t be impacted if they’re forced to restate their financials because of the way they accounted for warrants in a SPAC transaction, CFO Dive reports, citing a Moody’s analysis.
Top SPAC Sponsors Pulling IPOs at a Record Clip
Dealmakers aborted at least 14 planned listings this month alone for SPACs that were looking to raise a combined $4 billion.
SPAC vs Traditional IPO: Investors See Benefits of Blank-Check Companies
This article from Crunchbase looks at SPAC deal flow in 2020 and the potential upside of investing in blank-check companies led by experienced executive teams.
Private Investors Plot Forbes Buyout Over SPAC Deal
Forbes previously announced plans to go public via a SPAC merger that was set to close in Q4 of this year or Q1 2022.